Borim Lee
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Borim Lee has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Byung Kwan Choi
Department of Neurosurgery and Medical Research Institute, Pusan National University Hospital, Pusan National University School of Medicine, Busan, Korea
1 shared publication - Da Eun Lee
College of Pharmacy, Seoul National University, Seoul, Republic of Korea
1 shared publication - Geunho Lim
College of Pharmacy Seoul National University Seoul Republic Of Korea
1 shared publication - In-Wha Kim
Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul, Republic of Korea
1 shared publication - Jeongmin Seo
Department of Internal Medicine Seoul National University Bundang Hospital, Seoul National University College of Medicine Seongnam Republic of Korea
1 shared publication - Ji Sun Chun
College of Pharmacy, Seoul National University, Seoul, Republic of Korea
1 shared publication
Latest Publications
- Open Access
- 4 August 2026
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 120 (4) , 1129-1141
Early and High‐Dose Glucocorticoid Use and Survival in Advanced NSCLC Receiving Immune Checkpoint Inhibitors: A Multicenter Target Trial Emulation
Despite the immunomodulatory mechanism of immune checkpoint inhibitors (ICIs), systemic glucocorticoids are commonly used in advanced non–small cell lung cancer (NSCLC). Evidence regarding their effects on ICI outcomes is inconsistent, in part due to confounding by indication and immortal time bias. We conducted a multicenter target trial emulation to assess the association of glucocorticoid timing and dose with survival outcomes while addressing these biases. Patients with advanced NSCLC who initiated ICI therapy between 2015 and 2021 at four Korean tertiary hospitals were included. The primary endpoint was 2‐year overall survival (OS), with disease progression as a secondary endpoint. To minimize biases, outcomes were compared between concomitant glucocorticoid users and non‐users using time‐dependent propensity score matching. Among 1,815 eligible patients, 1,128 were matched. Hazard ratios (HRs) from the four institutions were pooled using a random‐effects meta‐analysis. Concomitant glucocorticoid use was associated with an increased risk of mortality (pooled aHR 1.36; 95% CI, 1.06–1.75). Early exposure within 90 days of ICI initiation was associated with poorer OS (aHR 1.49; 95% CI, 1.18–1.87), whereas later initiation showed no association. Dose‐stratified analyses showed that high‐dose exposure (> 1 mg/kg/day) was associated with reduced survival (aHR 1.61; 95% CI, 1.31–1.99), whereas low‐dose exposure was not associated with adverse outcomes. After accounting for confounding by indication and time‐related biases, concomitant systemic glucocorticoid use during ICI therapy was associated with less favorable survival outcomes. This association was more pronounced with early and high‐dose exposure, underscoring the clinical importance of glucocorticoid timing and dose.
- 4 August 2026
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 120 (4) , 1129-1141
Open AccessEarly and High‐Dose Glucocorticoid Use and Survival in Advanced NSCLC Receiving Immune Checkpoint Inhibitors: A Multicenter Target Trial Emulation
Despite the immunomodulatory mechanism of immune checkpoint inhibitors (ICIs), systemic glucocorticoids are commonly used in advanced non–small cell lung cancer (NSCLC). Evidence regarding their effects on ICI outcomes is inconsistent, in part due to confounding by indication and immortal time bias. We conducted a multicenter target trial emulation to assess the association of glucocorticoid timing and dose with survival outcomes while addressing these biases. Patients with advanced NSCLC who initiated ICI therapy between 2015 and 2021 at four Korean tertiary hospitals were included. The primary endpoint was 2‐year overall survival (OS), with disease progression as a secondary endpoint. To minimize biases, outcomes were compared between concomitant glucocorticoid users and non‐users using time‐dependent propensity score matching. Among 1,815 eligible patients, 1,128 were matched. Hazard ratios (HRs) from the four institutions were pooled using a random‐effects meta‐analysis. Concomitant glucocorticoid use was associated with an increased risk of mortality (pooled aHR 1.36; 95% CI, 1.06–1.75). Early exposure within 90 days of ICI initiation was associated with poorer OS (aHR 1.49; 95% CI, 1.18–1.87), whereas later initiation showed no association. Dose‐stratified analyses showed that high‐dose exposure (> 1 mg/kg/day) was associated with reduced survival (aHR 1.61; 95% CI, 1.31–1.99), whereas low‐dose exposure was not associated with adverse outcomes. After accounting for confounding by indication and time‐related biases, concomitant systemic glucocorticoid use during ICI therapy was associated with less favorable survival outcomes. This association was more pronounced with early and high‐dose exposure, underscoring the clinical importance of glucocorticoid timing and dose.